ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
On Feb. 23, the American Chemical Society held a virtual ACS Pharma Leaders meeting. Thirty-four biopharma industry leaders, representing 17 firms, participated in the meeting. This event is a complement to the annual face-to-face ACS Pharma Leaders meeting that has been held since 2003.
The general topic was “What Are We Learning from COVID-19?” Wendy Young, senior vice president of small-molecule drug discovery at Genentech, served as the moderator, and ACS CEO Thomas Connelly delivered welcoming remarks. Speakers included Sylvie Sakata, head of external research solutions at Pfizer; Oliver Thiel, executive director of process development drug substance technologies and pivotal and commercial synthetics at Amgen; William Morris, senior research scientist at Merck & Co.; and Richard Mackman, vice president of medicinal chemistry at Gilead Sciences.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter